文献速递创面修复显微修复重建

Lymfactin® 1期研究:联合腺病毒VEGF-C与淋巴结移植治疗上肢淋巴水肿的24个月疗效与安全性结果

Phase 1 Lymfactin® Study: 24-month Efficacy and Safety Results of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2022-08-17

本研究为Lymfactin®联合微血管淋巴结移植手术(VLNT)治疗乳腺癌相关上肢淋巴水肿(BCRL)的延续研究,15例患者分别接受低剂量(1×10^10 vp,3例)或高剂量(1×10^11 vp,12例)Lymfactin®。高剂量组随访12个月时多余臂体积平均减少46%,12/12例中7例转运指数改善,生活质量问卷显示显著且持续改善。24个月随访期内Lymfactin®耐受性良好。

要点

  • 高剂量组12个月时多余臂体积平均减少46%,12例中7例转运指数改善。
  • 基线时脱除压缩衣7天手臂显著肿胀(105.7±161.0 ml,p=0.0253),12个月时肿胀较少且不显著(84.4±143.0 ml,p=0.0682)。
  • 24个月随访期内Lymfactin®耐受性良好,生活质量问卷显示显著且持续改善。

核心结论

  • 24个月随访期间,Lymfactin®耐受性良好,最有希望的发现是多余臂体积减少46%以及12个月时脱除压缩衣后体积增加不显著,提示有减轻淋巴水肿的潜力。

研究设计与样本

  • 本研究为Lymfactin®联合微血管淋巴结移植手术(VLNT)治疗乳腺癌相关上肢淋巴水肿(BCRL)患者的延续研究,含3年疗效和5年安全性随访。
  • 2016年6月至2018年2月期间共招募15例患者,3例接受低剂量(1×10^10病毒颗粒(vp)),12例接受高剂量(1×10^11 vp)Lymfactin®。

主要发现

  • 高剂量组随访12个月时多余臂体积平均减少46%,12例中7例转运指数改善。
  • 基线时脱除压缩衣7天导致显著手臂肿胀(105.7±161.0 ml,p=0.0253),12个月时脱除压缩衣后肿胀较少且不显著(84.4±143.0 ml,p=0.0682)。
  • 淋巴水肿生活质量量表(LQOLI或LyQLI)问卷显示生活质量显著且持续改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lymphedema is a common problem after breast cancer treatment. Lymfactin® is a prolymphangiogenic growth factor vector inducing the expression of human vascular endothelial growth factor C (VEGF-C). It promotes growth and repair of lymphatic vessels. METHODS: Lymfactin® was combined with microvascular lymph node transfer surgery (VLNT) to study the safety and efficacy of the treatment in breast cancer-related upper limb lymphedema (BCRL) patients. This is a continuation study with a 3 year efficacy and 5 year safety follow-up. RESULTS: Fifteen patients were recruited in the study between June 2016 and February 2018. Three patients received a lower dose (1 × 1010 viral particles (vp)), and 12 patients received a higher dose (1 × 1011 vp) of Lymfactin®, respectively. In the higher dose group, the reduction of excess arm volume was on average 46% after the 12 month follow-up, and the transport index was improved in 7/12 patients. At baseline, removal of the compression garment for 7 days resulted in significant arm swelling (105.7±161.0 ml, p=0.0253). However, at 12 months, there was less and not significant swelling after removal of the garment (84.4±143.0 ml, p=0.0682). Lymphedema Quality of Life Inventory (LQOLI or LyQLI) questionnaire showed significant and sustained improvement of quality of life. CONCLUSIONS: During 24 months' of follow-up, the results indicate that Lymfactin® is well tolerated. The most promising findings were a 46% reduction in excess arm volume and a nonsignificant volume increase after garment removal at 12 months, suggesting that there is potential for the reduction of lymphedema.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Leppäpuska IM, Hartiala P, Suominen S, et al. Phase 1 Lymfactin® Study: 24-month Efficacy and Safety Results of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema. J Plast Reconstr Aesthet Surg. 2022. PMID: 36151039. doi:10.1016/j.bjps.2022.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。